Inicio>>Signaling Pathways>> Others>>LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

Catalog No.GC34168

El diclorhidrato de LCL521 (diclorhidrato de 1,3DMG-B13) es un inhibidor de la ceramidasa Ácida (ACDasa). LCL521 también inhibe la esfingomielinasa Ácida lisosomal (ASMase).

Products are for research use only. Not for human use. We do not sell to patients.

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride) Chemical Structure

Cas No.: 1226759-47-2

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
462,00 $
Disponible
5mg
315,00 $
Disponible
10mg
495,00 $
Disponible
50mg
1.485,00 $
Disponible
100mg
2.385,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride) is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).

LCL521 (1 µM) acts as a potent inhibitor of cellular ACDase activity, whereas 10 µM LCL521 has an additional, decreased affect on the α-form of this enzyme. LCL521 (10µM) causes a time-dependent (1 hours and 5 hours) decrease of the α-ACDase form in MCF7 cells[1].

[1]. Bai A, et al. Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15;22(24):6933-44.

Reseñas

Review for LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LCL521 dihydrochloride (1,3DMG-B13 dihydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.